Monoclonal antibody-mediated blockade of myostatin, a member of the transforming growth factor-β (TGF-β) family of ligands, has been shown to increase muscle mass and volume in wild type mice and non-human primates and to increase muscle mass and improve function in murine models of DMD [226]. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.